🔬 The approach covers the entire vector manufacturing process, from transfection to purification, using adherent or suspension processes.
💡 AGC Bio is working to overcome challenges such as removing the final sterilization step and improving the polishing step of AAV manufacturing.
🌐 This standardized approach allows AGC Bio to be flexible and cater to clients’ needs in different phases of clinical trials.
Introduction:
AGC Biologics, a global contract developer, is offering a standardized approach to manufacturing adeno-associated viruses (AAVs) and lentiviruses (LVVs) for advanced therapies. This standardized approach covers the entire vector manufacturing process, providing flexibility to deal with client requests and different phases of clinical trials.
- AGC Biologics is among the first to offer a standardized approach to manufacturing AAVs and LVVs for advanced therapies.
- The standardized approach covers the entire vector manufacturing process, including transfection, purification, suspension, and adherent processes.
- AGC Biologics offers both adherent and suspension processes depending on client preferences and scalability needs.
- The company is working to overcome challenges such as removing the final sterilization step for lentivirus production and improving the polishing step of AAV manufacturing.
- Scaling down processes is important for testing new steps or making alterations to existing ones.
Conclusion:
AGC Biologics is providing a standardized approach to manufacturing AAVs and LVVs for advanced therapies, offering flexibility and scalability options to meet client needs. The company is also addressing challenges in the manufacturing process and emphasizes the importance of scaling down processes for testing and optimization.
